1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Rolling monthly submissions: Letters of Intent due by the 15th of each month (or following Monday if weekend). Full application due 4 weeks after invitation. No fixed annual deadline.
Bridge Funding for Disrupted Neurodegenerative Research Grant Program (BFDN) is sponsored by Alzheimer's Association and The Michael J. Fox Foundation for Parkinson's Research (with support from the Robertson Foundation).
This program aims to provide bridge or interim funding for salary and other direct costs for research projects focused on Alzheimer's disease, Frontotemporal Dementia, Parkinson's disease, Dementia with Lewy Bodies, atypical Parkinson's, and/or other related neurodegenerative di…
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Bridge Funding for Disrupted Neurodegenerative Research Grant Program (BFDN) Powering the Next Generation of Research | Parkinson's Disease Search for topics, articles, videos, research, etc...
Hit enter to search or ESC to close Bridge Funding for Disrupted Neurodegenerative Research Grant Program (BFDN) Powering the Next Generation of Research Bridge Funding for Disrupted Neurodegenerative Research Grant Program (BFDN) Powering the Next Generation of Research The Alzheimer’s Association and The Michael J.
Fox Foundation for Parkinson’s Research are launching the Bridge Funding for Disrupted Neurodegenerative Research (BFDN) grant program. U.S. federal government-sponsored research funding has experienced a series of changes that challenges ongoing research initiatives and the future of the U.S. biomedical research enterprise.
Maintaining continuity of funding for these projects enables further scientific progress and is critical to millions of Americans affected by Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders and age-related causes of dementia — and millions more who may be affected by these diseases in the future, as rates for neurological disease are increasing around the world and expected to double as age is the biggest risk factor.
Recent advances in Alzheimer’s and Parkinson’s disorders research show tremendous promise, and ensuring funding for priority research grants is vital for investigators to effectively and efficiently perform life-saving research and carry- out public health programs toward better health outcomes for the United States — and the world.
As the world’s largest nonprofit funders with a shared commitment and purpose to deliver better treatments and a cure for (respectively) Alzheimer’s, Parkinson’s and related disorders, the Alzheimer’s Association and The Michael J. Fox Foundation for Parkinson’s Research are launching the Bridge Funding for Disrupted Neurodegenerative Research (BFDN) grant program.
The Alzheimer’s Association has partnered with the Robertson Foundation to support this unique funding program.
This program specifically aims to 1) ensure support for early career researchers (based on NIH definition), who have not yet had the opportunity to fully establish their labs and position their projects for ongoing funding, and 2) provide bridge or interim funding for salary and other direct costs for research projects focused on Alzheimer’s disease, Frontotemporal Dementia, Parkinson’s disease, Dementia with Lewy Bodies, atypical Parkinson's and/or other related disorders that have been impacted by a series of changes at NIH.
Funding and award period: Principal investigators may apply for bridge funding spanning 3 to 12 months for U.S. and international projects impacted by changes in the NIH. Specific streams of funding include: Delayed Review: Projects stalled due to NIH review process delays. Termination: Laboratories whose NIH grants have been terminated due to changes in funding priorities and/or area of interest and are seeking other permanent funding.
Priority Misalignment: Projects that no longer fit NIH focus areas requiring redirection to align with reframing to reflect adjusted priorities and areas of interest. Gaps: Previously funded projects awaiting reapproval under new criteria. Personnel Continuity: Salary support for key personnel due to changes in project timelines.
Here. Until Parkinson's isn't. Help us speed a cure for the 6 million people worldwide living with Parkinson's.
Join our email list to get the latest news and resources directly to your inbox. Connection to Parkinson's Immediate family member has PD Immediate family member had PD Extended family member or friend has PD Extended family member or friend had PD I am a researcher, clinician or work with the PD community What Year Were You Diagnosed with PD?
According to the current listing, eligibility includes: Early Stage Investigators per NIH guidelines whose NIH grant has been disrupted and need interim funding. Research must focus on Alzheimer's disease, FTD, Parkinson's disease, Dementia with Lewy Bodies, atypical Parkinson's, or related neurodegenerative disorders. Confirm the full requirements in the official notice before applying.
Bridge Funding for Disrupted Neurodegenerative Research Grant Program (BFDN) is funded by Alzheimer's Association and The Michael J. Fox Foundation for Parkinson's Research (with support from the Robertson Foundation). Verify program details on the funder's official page before applying.
This listing is flagged as international in scope. Check the official notice for country-specific restrictions before applying.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
On August 26, 2026, NSF named the STC class of 2026: TEMPEST at Michigan State, GENIE at Northwestern, and a human-robot co-adaptation center at UT Austin. $90 million total, $6 million a year each. The 2023 class was four centers and $120 million. The award size is intact; the shelf space shrank 25 percent — and that is the number that should reshape how you plan a center proposal.
Read articleWith Forms J in FY2027, NIH will no longer accept letters of support — the boilerplate endorsements applicants have padded proposals with for decades. Notice NOT-OD-26-094 replaces them with letters of collaboration, aligning NIH with NSF. Here is exactly what changes, what a compliant letter must now contain, who can no longer write one, and how this fits the broader re-engineering of the NIH application package.
Read articleThe NIH Common Fund launched PRIMED-AI — Precision Medicine with AI: Integrating Imaging with Multimodal Data — as five coordinated funding opportunities (RFA-RM-27-011 through -015) that build a full pipeline from standards to clinic. Here is how the Playbook, Data-to-Model partnerships, Model-to-Clinic translation, Validation Center, and Logistics Center fit together, what each pays, who is eligible, and how to position before the October 2026 deadlines.
Read article